Adding Ebola to the FDA Priority Review Voucher Program Act

Hozzl · 2024-03-14T12:48:43Z

Explore the details of Senate Bill 2917 Adding Ebola to the FDA Priority Review Voucher Program Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/14/2024, 12:48 PM

Congressional Summary of S 2917

(This measure has not been amended since it was introduced. The expanded summary of the Senate reported version is repeated here.)

Adding Ebola to the FDA Priority Review Voucher Program Act - (Sec. 2) Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.)

Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS).

Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times.

Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 2917

Bill S 2917 is currently in the status of Bill Introduced since November 12, 2014. Bill S 2917 was introduced during Congress 113 and was introduced to the Senate on November 12, 2014. Bill S 2917's most recent activity was Became Public Law No: 113-233. as of December 16, 2014

Bipartisan Support of Bill S 2917

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 2917

Primary Policy Focus

Health

Potential Impact Areas

Drug safety, medical device, and laboratory regulationDrug therapyInfectious and parasitic diseases

Alternate Title(s) of Bill S 2917

Adding Ebola to the FDA Priority Review Voucher Program ActA bill to expand the program of priority review to encourage treatments for tropical diseases.Adding Ebola to the FDA Priority Review Voucher Program ActAdding Ebola to the FDA Priority Review Voucher Program ActAdding Ebola to the FDA Priority Review Voucher Program ActAdding Ebola to the FDA Priority Review Voucher Program ActAdding Ebola to the FDA Priority Review Voucher Program Act

Start holding our government accountable!